Pharmaceutical Executive-04-02-2008

With M&As the new R&D and sales forces getting axed, the CFO is transitioning from background player to front man. A new survey documents the changing role of the pharma controller.

While some drugmakers are being pummeled for data on their "bad" cholesterol?lowering drugs, promising Phase II stats about its "good" cholesterol?raising CETP inhibitor has Roche smiling. Can it escape the torcetrapib curse?

California's plan for full-blown ePedigree implementation by 2009 just got a reality check. The hang-up? The systems are cost more and are taking longer than expected to get up and running.